Premium
Clinical impact of tamsulosin on generic and symptom‐specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and Rand Medical Outcomes Study 36‐item Health Survey
Author(s) -
SUZUKI HIROYOSHI,
YANO MASASHI,
AWA YUSUKE,
NAKATSU HIROOMI,
EGOSHI KENICHI,
MIKAMI KAZUO,
OTA SHO,
OKANO TATSUYA,
HAMANO SATORU,
OHKI TAKEMASA,
FURUYA YUZO,
ICHIKAWA TOMOHIKO
Publication year - 2006
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01594.x
Subject(s) - medicine , tamsulosin , international prostate symptom score , quality of life (healthcare) , lower urinary tract symptoms , urology , prostate , prostatism , hyperplasia , prostate disease , nursing , cancer
Aim: To examine the efficiency of α1‐blocker treatment on disease‐specific and generic quality of life (QOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH), the improvement of QOL scores with International prostate symptom score (I‐PSS) and Rand Medical Outcomes Study 36‐item Health Survey (SF‐36) was prospectively analyzed. Methods: A total of 68 newly diagnosed patients with symptomatic BPH that satisfied all inclusion and none of the exclusion criteria were prospectively recruited. All patients received 0.2 mg/day of tamsulosin for 12 weeks. All patients underwent pretreatment documentation of lower urinary tract symptoms (LUTS) and assessment of symptom‐specific QOL. Symptoms and general health‐related QOL (HRQOL) were assessed using the I‐PSS and SF‐36, respectively. Also, other objective variables, such as prostate volume, maximal urinary flow and postvoid residual urine volume, were evaluated. Results: After 12 weeks, decrease in I‐PSS was 27% compared with baseline (from 16.4 ± 7.18 to 11.9 ± 7.56). All questionnaires in the I‐PSS showed improvement after tamsulosin treatment and the I‐PSS QOL score was improved from 4.51 ± 1.14 to 3.17 ± 1.38 ( P < 0.0001) at 12 weeks after tamsulosin administration. In intragroup comparisons of HRQOL scores with age‐gender adjusted SF‐36 Japanese national norms, three SF‐36 subscales (bodily pain, BP; social function, SF; and mental health, MH) were worse in the BPH group aged over 70 years, while younger BPH groups aged <70 had better mean SF‐36 physical function (PF) scores compared with age‐gender adjusted Japanese national norms. In the BPH group with a prostatic volume ≥20 mL, three mean SF‐36 scales (BP, SF and MH) were significantly improved after tamsulosin treatment. It is noteworthy that these SF‐36 subscales were identical to those observed to worsen in the older BPH group compared to Japanese national norms. Conclusions: Treatment with tamsulosin for symptomatic BPH patients is associated with significant improvement in the generic HRQOL, in addition to disease‐specific QOL and symptoms, at 3 months after drug administration. In particularly, for generic HRQOL with SF‐36, tamsulosin treatment can efficiently improve three mean SF‐36 subscales (BP, SF and MH) that are decreased in older BPH patients.